During the past decade, FILO French Innovative Leukemia Organization conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "FILO French Innovative Leukemia Organization" are "B Cell Chronic Lymphocytic Leukemia" (1 trials) and "Myelofibrosis" (1 trials). Many other conditions were trialed in "FILO French Innovative Leukemia Organization" in a lesser frequency.

Most popular intervention types in "FILO French Innovative Leukemia Organization" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ruxolotinib" (1 trials) and "peg-IFN alpha -2a" (1 trials). Other intervention names were less common.

The vast majority of trials in "FILO French Innovative Leukemia Organization" are 2 trials for "All" genders.

Currently, there are NaN active trials in "FILO French Innovative Leukemia Organization". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in FILO French Innovative Leukemia Organization, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in FILO French Innovative Leukemia Organization, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".